Home Alzheimer’s Disease Study Suggests a High Charlson Comorbidity Index Score Negatively Impacts OS, RS...

Study Suggests a High Charlson Comorbidity Index Score Negatively Impacts OS, RS in CLL

A study published in the International Journal of Environmental Research and Public Health revealed that among patients with chronic lymphocytic leukemia (CLL), a high Charlson comorbidity index (CCI) score negatively impacted overall survival (OS) and relative survival (RS).

However, when also considering age and Rai score, which indicates severity of CLL and comorbidities present at diagnosis, the effect of CCI score on mortality was found to be statistically nonsignificant for this patient population.

“These population-based data will provide insights into the relationship between comorbidities and CLL in a real-world setting,” wrote the study authors, who were led by Alicia Villavicencio.

Using the Girona Cancer Registry of Spain, the investigators extracted incident CLL cases diagnosed between 2008 and 2016. Of note, CLL and small lymphocytic lymphoma (SLL) cases were…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments